Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED THAT IT HAS FILED A PREMARKET APPROVAL SUPPLEMENT (PMA-S) APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SEEKING TO EXPAND THE LABELED INDICATION FOR ITS RNS SYSTEM TO INCLUDE PATIENTS WITH ANTISEIZURE-MEDICATION (ASM) RESISTANT IDIOPATHIC GENERALIZED EPILEPSY (IGE) WITH GENERALIZED TONIC-CLONIC SEIZURES.

NEUROPACE FILES PMA SUPPLEMENT TO FDA SEEKING EXPANDED RNS SYSTEM INDICATION FOR IDIOPATHIC GENERALIZED EPILEPSY

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, ANNOUNCED THE PRESENTATION AT THE AMERICAN EPILEPSY SOCIETY (AES) MEETING OF PRELIMINARY 18-MONTH SAFETY AND EFFECTIVENESS RESULTS FROM ITS ONGOING NAUTILUS1 TRIAL EVALUATING THE RNS SYSTEM AS AN ADJUNCTIVE THERAPY FOR THE TREATMENT OF ANTISEIZURE MEDICATION (ASM) RESISTANT IDIOPATHIC GENERALIZED EPILEPSY (IGE) WITH GENERALIZED TONIC.

NEUROPACE ANNOUNCES POSITIVE 18-MONTH NAUTILUS TRIAL RESULTS IN IDIOPATHIC GENERALIZED EPILEPSY

NEW YORK , DEC. 3, 2025 /PRNEWSWIRE/ -- BAIRD MEDICAL INVESTMENT HOLDINGS LTD. (NASDAQ: BDMD) ("BAIRD MEDICAL" OR THE "COMPANY"), A MARKET LEADER IN MINIMALLY INVASIVE MICROWAVE ABLATION (MWA) TECHNOLOGY, TODAY ANNOUNCED THE APPOINTMENT OF MARK SAXTON AS CHIEF EXECUTIVE OFFICER OF ITS U.S. SUBSIDIARY.

BAIRD MEDICAL APPOINTS MARK SAXTON AS U.S. CEO; TAPS VETERAN FROM NEUROPACE, SMITH + NEPHEW, AND COVIDIEN TO LEAD COMMERCIAL EXPANSION

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED THAT ITS RNS SYSTEM AND NEUROPACE AI PLATFORM WILL BE PROMINENTLY FEATURED AT THE 2025 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING IN ATLANTA, GEORGIA WHERE NEUROPACE WILL FEATURE NEW CLINICAL AND AI-DRIVEN ADVANCES THAT UNDERSCORE THE COMPANY'S FOCUS ON DELIVERING LIFE-CHANGING OUTCOMES AND ENABLING PHYSICIANS TO P.

NEUROPACE TO HIGHLIGHT LIFE-CHANGING OUTCOMES AND AI-POWERED CONFIDENT CARE AT THE 2025 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED FAVORABLE MEDICARE REIMBURSEMENT UPDATES FOR THE RNS SYSTEM UNDER BOTH THE CY 2026 OPPS AND MEDICARE PFS FINAL RULES. IN THE CY 2026 MEDICARE PFS FINAL RULE, THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) SIGNIFICANTLY INCREASED PROFESSIONAL PAYMENT FOR NEUROSURGEONS WHO IMPLANT AND REPLACE THE RNS SYSTEM.

NEUROPACE ANNOUNCES FAVORABLE MEDICARE REIMBURSEMENT INCREASES FOR RNS SYSTEM PHYSICIAN AND HOSPITAL OUTPATIENT SERVICES

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. THIRD QUARTER 2025 FINANCIAL HIGHLIGHTS TOTAL REVENUE OF $27.4 MILLION, REPRESENTING GROWTH OF 30% COMPARED TO THE THIRD QUARTER OF 2024 RNS SYSTEM REVENUE OF $22.6 MILLION, REPRESENTING GROWTH OF 31% COMPARED TO THE THIR.

NEUROPACE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND INCREASES 2025 REVENUE GUIDANCE

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 AFTER MARKET CLOSE ON TUESDAY, NOVEMBER 4, 2025. THE COMPANY'S MANAGEMENT WILL WEBCAST A CORRESPONDING CONFERENCE CALL BEGINNING AT 1:30 P.M. PACIFIC TIME (4:30 P.M. EASTERN TIME). INVESTORS INTERESTED IN LISTENING TO THE CONFERENCE CALL MAY DO SO BY ACCESS.

NEUROPACE TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 4, 2025

-- REPORTED RECORD QUARTERLY REVENUE OF $23.5 MILLION IN Q2 2025-- -- INCREASED FULL-YEAR 2025 REVENUE GUIDANCE TO BETWEEN $94 MILLION AND $98 MILLION AND GROSS MARGIN GUIDANCE TO BETWEEN 75% AND 76%-- -- REMAIN ON TRACK TO SUBMIT NAUTILUS DATA TO FDA FOR POTENTIAL IGE INDICATION EXPANSION IN THE SECOND HALF OF 2025 --CMS MAINTAINS CURRENT MS-DRG ASSIGNMENT FOR RNS SYSTEM PROCEDURES-- MOUNTAIN VIEW, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

NEUROPACE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND INCREASES 2025 REVENUE GUIDANCE

MOUNTAIN VIEW, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ISSUED THE FOLLOWING STATEMENT IN RESPONSE TO THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) ELECTING NOT TO FINALIZE ITS PROPOSED REASSIGNMENT OF EPILEPSY WITH NEUROSTIMULATOR CASES IN THE FY 2026 INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS) RULE.

NEUROPACE COMMENDS CMS FOR MAINTAINING FY25 REIMBURSEMENT STRUCTURE FOR EPILEPSY WITH NEUROSTIMULATOR CASES

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ: NPCE).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NeuroPace, Inc.

NPCE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NeuroPace, Inc.

NPCE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NPCE